Entering text into the input field will update the search result below

Merck's talks with Seagen said to hit obstacle over price - report

Aug. 25, 2022 9:07 PM ETSeagen Inc. (SGEN), MRKBy: Joshua Fineman, SA News Editor11 Comments

Merck & Co. headquarters in Silicon Valley

Sundry Photography

  • Merck & Co.'s (NYSE:MRK) discussions to purchase cancer-drug company Seagen (NASDAQ:SGEN) are said to have been put on hold.
  • The talks are said to have ended over a disagreement on price, according to a Bloomberg report. The

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.